- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06121869
Dileucine and Resistance Training Adaptations (DTS)
November 2, 2023 updated by: Lindenwood University
A Pilot Study to Examine Changes in Resistance Training Adaptations After Leucine and Dileucine Ingestion
This study seeks to compare the observed changes in resistance training adaptations after supplementation of isomolar amounts of leucine or dileucine in healthy resistance-trained men.
This will provide a better understanding of supplementation with leucine versus dileucine over a 10-week period in regards to increasing muscular performance.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The study will be conducted using a randomized, double-blind approach with individuals being provided daily 2-gram doses of leucine, 2-gram doses of dileucine, or a placebo.
Daily blinded supplementation will occur each day for a 10-week period of time while completing a heavy resistance training program.
Participants follow the resistance training program for a total of 10 weeks.
To compare the efficacy of leucine in form of amino acid or dipeptide supplementation on resistance training adaptations, changes in fat-free, lean, and fat mass will be determined using a 4-compartment body composition model.
Skeletal muscle cross-sectional area will be assessed using ultrasound.
Maximal strength, muscular endurance, and power will also be assessed.
Participants will be required to provide weekly compliance and complete one supervised workout per week.
After 2, 6, and 10 weeks of following the supplementation and resistance training regimens, participants will return to the laboratory to complete testing bouts consisting of identical assessments of body composition, muscular strength, muscular endurance, lower-body power, and anaerobic capacity.
Adverse events related to each supplementation group will be recorded and assessed.
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Saint Charles, Missouri, United States, 63301
- Exercise and Performance Nutrition Laboratory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male
- Between the ages of 18-39 years of age
- Currently participating in resistance training exercise
Exclusion Criteria:
- Female
- Participants who are determined to not be weight stable defined as week 0 and week 2 body mass levels deviating by 3% or more.
- Any individual who is currently being treated for or diagnosed with a cardiac, respiratory, circulatory, musculoskeletal, metabolic, immune, autoimmune, psychiatric, hematological, neurological or endocrinological disorder or disease.
- Body mass index > 25 kg/m2. Individuals with a body mass index greater than 25 kg/m2, but a body fat percentage less than 25% fat will be accepted into the study
- Individuals who present with any previous injury or illness that would prevent them from appropriately completing all exercise lifts.
- Participants who are not able to fit onto the DEXA table will not be able to participate in the research due to size restrictions of the equipment. This typically includes individuals exceeding 400 pounds or those greater than 6'4".
- Those individuals with less than 12 months of structured resistance training experience will be excluded from the study.
- Individuals whose maximal relative upper body strength is below 1.0 will be excluded.
- Individuals whose maximal relative lower body strength is below 1.5 will be excluded.
- All participants who DO NOT abstain from taking any additional forms of nutritional supplementation deemed to be ergogenic or that will impact resistance training adaptations (pre-workouts, creatine, beta-alanine, etc.) for four weeks prior to beginning this study and for the entire duration of the study.
- Individuals who are currently using or have used within the past 12 months anabolic-androgenic steroids.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form.
On training days, participants will consume their assigned supplement within 60 minutes of completing their workout.
On non-training days, participants will consume their assigned supplement with their first meal of the day.
All doses will be consumed with 8-12 ounces of water.
|
Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form.
On training days, participants will consume their assigned supplement within 60 minutes of completing their workout.
On non-training days, participants will consume their assigned supplement with their first meal of the day.
All doses will be consumed with 8-12 ounces of water.
|
|
Active Comparator: Leucine
Participants will supplement daily for 10 weeks with 2 grams rice leucine in capsule form.
On training days, participants will consume their assigned supplement within 60 minutes of completing their workout.
On non-training days, participants will consume their assigned supplement with their first meal of the day.
All doses will be consumed with 8-12 ounces of water.
|
Participants will supplement daily for 10 weeks with 2 grams leucine in capsule form.
On training days, participants will consume their assigned supplement within 60 minutes of completing their workout.
On non-training days, participants will consume their assigned supplement with their first meal of the day.
All doses will be consumed with 8-12 ounces of water.
|
|
Experimental: Dileucine
Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form.
On training days, participants will consume their assigned supplement within 60 minutes of completing their workout.
On non-training days, participants will consume their assigned supplement with their first meal of the day.
All doses will be consumed with 8-12 ounces of water.
|
Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form.
On training days, participants will consume their assigned supplement within 60 minutes of completing their workout.
On non-training days, participants will consume their assigned supplement with their first meal of the day.
All doses will be consumed with 8-12 ounces of water.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fat-Free Mass
Time Frame: 10 weeks
|
Fat-free mass will be determined via Dual-Energy X-Ray Absorptiometry
|
10 weeks
|
|
Leg Press 1RM
Time Frame: 10 weeks
|
Leg Press 1RM will be measured using the leg press (lower-body) exercise.
|
10 weeks
|
|
Bench Press 1RM
Time Frame: 10 weeks
|
Bench Press 1RM will be measured using the bench press (upper-body) exercise.
|
10 weeks
|
|
Maximal Isometric Mid-Thigh Pull Force Production
Time Frame: 10 weeks
|
Maximal Isometric Mid-Thigh Pull Force Production will be measured using an isometric mid-thigh pull test
|
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fat Mass
Time Frame: 10 weeks
|
Fat mass will be determined via Dual-Energy X-Ray Absorptiometry
|
10 weeks
|
|
Lean mass
Time Frame: 10 weeks
|
Lean mass will be determined via Dual-Energy X-Ray Absorptiometry
|
10 weeks
|
|
% Body Fat
Time Frame: 10 weeks
|
% Body Fat will be determined via Dual-Energy X-Ray Absorptiometry
|
10 weeks
|
|
Total body water
Time Frame: 10 weeks
|
Total Body Water will be determined via bioelectrical impedance analysis
|
10 weeks
|
|
Extracellular Body Water
Time Frame: 10 weeks
|
Extracellular Body Water will be determined via bioelectrical impedance analysis
|
10 weeks
|
|
Intracellular Body Water
Time Frame: 10 weeks
|
Intracellular Body Water will be determined via bioelectrical impedance analysis
|
10 weeks
|
|
Skeletal muscle cross-sectional area
Time Frame: 10 weeks
|
Skeletal muscle cross-sectional area will be measured using ultrasound measurements of the participants thigh muscles.
|
10 weeks
|
|
Bench Press Repetitions to Fatigue
Time Frame: 10 weeks
|
Bench Press repetitions to fatigue will be measured using the bench press (upper-body) exercises on four separate occasions (visits 2, 3, 4, and 5).
To complete this assessment, study participants will use a load that corresponds to 80% of their Visit 2 1RM for bench press exercise and will be instructed to complete as many repetitions as they can until failure for one set of each exercise.
Failure will be defined as resting for more than two seconds throughout any point on the exercise set or technique failure.
|
10 weeks
|
|
Leg Press Repetitions to Fatigue
Time Frame: 10 weeks
|
Leg Press repetitions to fatigue will be measured using the leg press (lower-body) exercises on four separate occasions (visits 2, 3, 4, and 5).
To complete this assessment, study participants will use a load that corresponds to 80% of their Visit 2 1RM for leg press exercise and will be instructed to complete as many repetitions as they can until failure for one set of each exercise.
Failure will be defined as resting for more than two seconds throughout any point on the exercise set or technique failure.
|
10 weeks
|
|
Peak Anaerobic Power
Time Frame: 10 weeks
|
Peak Anaerobic Power will be measured using a Wingate Anaerobic Test lasting 30-seconds at a load set to 7.5% of week 0 body mass
|
10 weeks
|
|
Mean Anaerobic Power
Time Frame: 10 weeks
|
Mean Anaerobic Power will be measured using a Wingate Anaerobic Test lasting 30-seconds at a load set to 7.5% of week 0 body mass
|
10 weeks
|
|
Rate of Fatigue
Time Frame: 10 weeks
|
Rate of Fatigue will be measured using a Wingate Anaerobic Test lasting 30-seconds at a load set to 7.5% of week 0 body mass
|
10 weeks
|
|
Maximal Concentric Rate of Force Development
Time Frame: 10 weeks
|
Maximal concentric rate of force development will be measured using a countermovement jump performed on a force plate
|
10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Chad M Kerksick, PhD, Lindenwood University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2021
Primary Completion (Actual)
June 29, 2023
Study Completion (Actual)
June 29, 2023
Study Registration Dates
First Submitted
November 2, 2023
First Submitted That Met QC Criteria
November 2, 2023
First Posted (Actual)
November 8, 2023
Study Record Updates
Last Update Posted (Actual)
November 8, 2023
Last Update Submitted That Met QC Criteria
November 2, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-41-64
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No plan to make individual participant data available to other researchers
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophy
-
Nationwide Children's HospitalActive, not recruitingSurgery | Tonsillar Hypertrophy | Adenoid HypertrophyUnited States
-
Rhode Island HospitalCompletedChildren, Only | Tonsillar Hypertrophy | Adenoid HypertrophyUnited States
-
Nagoya UniversityUnknownHypertensive Left Ventricular HypertrophyJapan
-
Sohag UniversityNot yet recruitingLeft Ventricular Hypertrophy
-
Gaziosmanpasa Research and Education HospitalNot yet recruitingTonsillar Hypertrophy | Voice Disorders in Children | Adenoid HypertrophyTurkey (Türkiye)
-
Organon and CoCompleted
-
Istanbul UniversityWithdrawn
-
Seoul National University HospitalSamsung Medical Center; Chung-Ang University Hosptial, Chung-Ang University... and other collaboratorsCompletedTonsillar HypertrophyKorea, Republic of
-
Marymount UniversityUniversity of TehranCompleted
-
Pierre-Yves P LequeuxCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States